



Results of the: 05/06/2006 200606PP2 Proof of Principle Phase 2

Updated: 26/10/2006

Name(s) Institution Title	CIHR Contribution	Partner	Partner(s) Contribution	Term	Status
GORDON, John R University of Saskatchewan Indications and mechanisms assessment for a novel human ELR-CXC chemokine antagonist	\$ 80,793	Pacgen Biopharmaceuticals Corporation (Saskatoon)	\$ 161,587	1 Yr(s)	
KHALIL, Nasreen University of British Columbia Therapeutic Applications of CD36 93-110 Peptide in Progressive and Lethal Diseases	\$ 67,933	Pacific Therapeutics Ltd. (Vancouver, BC)	\$ 135,866	1 Yr(s)	Pending
WANG, Yu Tian University of British Columbia LTD blocking peptide as a therapy for neuropsychiatric illnesses	\$ 250,000	Stratford Pharmaceuticals Ltd. (Vancouver)	\$ 500,000	1 Yr(s)	